Immunohistochemical and Molecular Study of Epstein–Barr virus (EBV) Expression in Lymphoma and Its Correlation with Age , Gender of Patients and Type of Lymphoma in Thi-Qar
Keywords:
PCR, a manual LSAB procedure, EBV, NHL, HLAbstract
Background: The lymphoid malignancies comprise one of the most diverse and heterogeneous sets of diseases that exist under a single type of malignancy. In 2012, the American Cancer Society estimated there were about 70,000 cases of non-Hodgkin lymphoma (NHL), and about 10,000 cases of Hodgkin lymphoma in the United States, collectively accounting for about 4% to 5% of all cancers. The estimated number of U.S. cancer deaths attributed to lymphoma is about 3% for both males and females, ranking it about 8th among all causes of cancer death. Hodgkin lymphoma typically carries a better prognosis, accounting for approximately 1000 deaths per year. Whereas the lifetime risk of developing any cancer is about 1 in 2 for males and 1 in 3 for females, the lifetime risk of developing non-Hodgkin lymphoma is about 1 in 43 and 1 in 51 for males and females, respectively (for the years between 2006 and 2008). Since the discovery in 1964 of the Epstein–Barr virus (EBV) in African Burkitt lymphoma, this virus has been associated with a remarkably diverse range of cancer types. Because EBV persists in the B cells of the asymptomatic host, it can easily be envisaged how it contributes to the development of B-cell lymphomas. However, EBV is also found in other cancers, including T-cell/natural killer cell lymphomas and several epithelial malignancies. Explaining the etiological role of EBV is challenging, partly because the virus probably contributes differently to each tumour and partly because the available disease models cannot adequately recapitulate the subtle variations in the virus–host balance that exist between the different EBV-associated cancers . Aim of the study:- To assess EBV over expression in lymphoma and its correlation with age , gender of patients and type of lymphoma . Materials and methods: this study was included 93 cases of archival lymphoid tissue, collected randomly from the period of February 2015- April 2017 from Al-imam Al-hussein Teaching Hospital and some private laboratories in Thi-Qar government . 41 patients of non Hodgkin’s lymphoma (NHL) and 52 patients of Hodgkin’s lymphoma (HL) ,their median age 50.04 years range from (14–70 )years . A manual LSAB procedure was used in the imunohistochemical (IHC) analysis (DakoCytomation Copenhagen ,Denmark) and polymerase chain reaction (PCR) procedure was used in the molecular analysis (Bioneer company, Korea). Results: IHC analysis of EBV over expression was positive in (17.1%) of NHL and (42.3%) of HL , while PCR analysis of EBV over expression was positive in (31.7%) of NHL and (61.5%) of HL were correlated with age of patients and type of tumor, Conclusion: These finding support the role of EBVs in carcinogenesis of lymphoma regarding behavior and aggressiveness.References
^ Jump up to: a b Taylor, Elizabeth J. (2000). Dorland's Illustrated medical dictionary. (29th ed.). Philadelphia: Saunders. p. 1038. ISBN 0721662544.
^ Jump up to: a b c d e f g h i j k "General Information About Adult Hodgkin Lymphoma". National Cancer Institute. 2014-04-23. Archived from the original on 5 July 2014. Retrieved 20 June 2014.
^ Jump up to: a b c d e f g h i j k l m n "General Information About Adult Non-Hodgkin Lymphoma". National Cancer Institute. 2014-04-25. Archived from the original on 5 July 2014. Retrieved 20 June 2014.
Jump up ^ Aditya Bardia (2010). Johns Hopkins Patients' Guide to Lymphoma. Jones & Bartlett Learning. p. 6. ISBN 9781449631413. Archived from the original on 2017-09-10.
^ Jump up to: a b c The Lymphoma Guide Information for Patients and Caregivers (pdf). Leukemia and Lymphoma Society. 2013. Archived (PDF) from the original on 14 July 2014. Retrieved 20 June 2014.
^ Jump up to: a b c d World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 5.13. ISBN 9283204298.
Jump up ^ "Lymphoma". NCI. Archived from the original on 5 July 2014. Retrieved 13 June 2014.
Jump up ^ Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD (Jul 30, 2009). "The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.". Blood. 114 (5): 937–51. PMID 19357394. doi:10.1182/blood-2009-03-209262.
Jump up ^ Hu, L; Luo, D; Zhou, T; Tao, Y; Feng, J; Mei, S (12 August 2017). "The association between non-Hodgkin lymphoma and organophosphate pesticides exposure: A meta-analysis.". Environmental pollution (Barking, Essex : 1987). 231 (Pt 1): 319–328. PMID 28810201. doi:10.1016/j.envpol.2017.08.028.
Jump up ^ Yang, L; Dong, J; Jiang, S; Shi, W; Xu, X; Huang, H; You, X; Liu, H (November 2015). "Red and Processed Meat Consumption Increases Risk for Non-Hodgkin Lymphoma: A PRISMA-Compliant Meta-Analysis of Observational Studies.". Medicine. 94 (45): e1729. PMC 4912242 . PMID 26559248. doi:10.1097/MD.0000000000001729.
Jump up ^ Solimini, AG; Lombardi, AM; Palazzo, C; De Giusti, M (May 2016). "Meat intake and non-Hodgkin lymphoma: a meta-analysis of observational studies.". Cancer causes & control : CCC. 27 (5): 595–606. PMID 27076059. doi:10.1007/s10552-016-0745-2.
^ Jump up to: a b Kamper-Jørgensen, M; Rostgaard, K; Glaser, SL; Zahm, SH; Cozen, W; Smedby, KE; Sanjosé, S; Chang, ET; Zheng, T; La Vecchia, C; Serraino, D; Monnereau, A; Kane, EV; Miligi, L; Vineis, P; Spinelli, JJ; McLaughlin, JR; Pahwa, P; Dosman, JA; Vornanen, M; Foretova, L; Maynadie, M; Staines, A; Becker, N; Nieters, A; Brennan, P; Boffetta, P; Cocco, P; Hjalgrim, H (September 2013). "Cigarette smoking and risk of Hodgkin lymphoma and its subtypes: a pooled analysis from the International Lymphoma Epidemiology Consortium (InterLymph).". Annals of Oncology. 24 (9): 2245–55. PMC 3755332 . PMID 23788758. doi:10.1093/annonc/mdt218.
Butler J J 1992 The histologic diagnosis of Hodgkin’s disease. Semin Diagn Pathol 9: 252-256
Stein H, Diehl V, Marafioti T et al. 1999 The nature of Reed- Sternberg cells, lymphocytic and histiocytic cells and their molecular biology in Hodgkin’s disease. In: Mauch P M, Armitage J O, Diehl V et al (eds) Hodgkin’s disease. Lippincott Williams & Wilkins, Philadelphia, p 121-137
Stein H S, Hummel M 1999 Hodgkin’s disease: biology and origin of Hodgkin and Reed-Sternberg cells. Cancer Treat Rev 25: 161-168
Liang R, Choi P, Todd D et al. 1989 Hodgkin’s disease in Hong Kong Chinese. Hematol Oncol 7: 395-403.
Said J W 1997 Human immunodeficiency virus–related lymphoid proliferations. Semin Diagn Pathol 14: 48-53.
Audouin J, Diebold J, Pallesen G 1992 Frequent expression of Epstein-Barr virus latent membrane protein-1 in tumor cells of Hodgkin’s disease in HIV-positive patients. J Pathol 167: 381-384.
Tirelli U, Carbone A, Straus D J 1999 HIV-related Hodgkin’s disease. In: Muach P M, Armitage J O, Diehl V et al (eds) Hodgkin’s disease. Lippincott Williams & Wilkins, Philadelphia, p 701-711.
Carbone A, Gloghini A, Larocca L M et al. 1999 Human immunodeficiency virus–associated Hodgkin’s disease derives from post–germinal center B cells. Blood 93: 2319-2326 .
Harris N L, Jaffe E S, Stein H et al. 1994 A revised European- American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84: 1361-1392.
Harris N L 1998 The many faces of Hodgkin’s disease around the world: what have we learned from its pathology? Ann Oncol 9: S45-S56.
Harris N L 1999 Hodgkin’s lymphomas: classification, diagnosis, and grading. Semin Hematol 36: 220-232
Harris N L 1999 Hodgkin’s disease: classification and differential diagnosis. Mod Pathol 12: 159-175.
Harris N L, Jaffe E S, Diebold J et al. 1999 World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997. J Clin Oncol 17: 3835-3849.
Chan J K, Banks P M, Cleary M L et al. 1995 A revised European- American classification of lymphoid neoplasms proposed by the International Lymphoma Study Group. A summary version. Am J Clin Pathol 103: 543-560.
Chan J K, Banks P M, Cleary M L et al. 1994 A proposal for classification of lymphoid neoplasms (by the International Lymphoma Study Group). Histopathology 25: 517-536.
Lukes R J 1971 Criteria for involvement of lymph node, bone marrow, spleen, and liver in Hodgkin’s disease. Cancer Res 31: 1755-1767.
Dorfman R F, Colby T V 1982 The pathologist’s role in management of patients with Hodgkin’s disease. Cancer Treat Rep 66:675-680.
Carbone P, Kaplan H S, Musshoff K 1971 Report of the committee on Hodgkin’s disease staging classification. Cancer Res 31: 1860-1861.
Lister T A, Crowther D, Sutcliffe S B et al. 1989 Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 7: 1630-1636.
Swerdlow SH, et al.WHO classification of tumours of haematopoietic and lymphoid tissues. In: World Health Organization Classification of Tumours. Lyon,France: IARC. In press.
